Induced Pluripotent Stem Cell

Induced Pluripotent Stem Cell (iPSC) is a self-renewing pluripotent stem cell line derived experimentally from a differentiated somatic cell—such as a dermal fibroblast, peripheral blood mononuclear cell, or urinary renal epithelial cell—by resetting somatic chromatin and transcriptional networks back to an embryonic epiblast-like state. Whereas somatic cell nuclear transfer demonstrated in frogs (John B. Gurdon, 1962) and sheep (Ian Wilmut, 1996) that oocytes contain factors capable of erasing somatic identity, Shinya Yamanaka and Kazutoshi Takahashi proved in 2006 (mouse) and 2007 (human, concurrently with James A. Thomson and Junying Yu) that four defined transcription factors reprogram adult somatic cells without embryos or oocytes—a discovery recognized with the 2012 Nobel Prize in Physiology or Medicine.

To identify minimal drivers of pluripotency, Takahashi and Yamanaka engineered mouse fibroblasts carrying a neomycin-resistance/β-galactosidase reporter at the Fbx15 locus and screened retroviral pools of 24 candidate embryonic factors. Leave-one-out withdrawal narrowed the active cocktail to four factors (OSKM): the POU-homeodomain factor OCT4 (POU5F1), the HMG-box partner SOX2, the Krüppel-like zinc-finger factor KLF4, and the basic helix-loop-helix proto-oncogene c-MYC (MYC). Selecting on endogenous Nanog or Oct4 reactivation yielded germline-competent mouse iPSCs capable of generating chimeric mice.

In November 2007, Takahashi and Yamanaka reprogrammed adult human dermal fibroblasts using human OCT4, SOX2, KLF4, and c-MYC, while Yu, Thomson, and colleagues independently reprogrammed human somatic cells using OCT4, SOX2, NANOG, and the RNA-binding protein LIN28A (which blocks maturation of differentiation-promoting let-7 microRNAs), showing that c-MYC is optional whereas OCT4 and SOX2 form the non-redundant core reversing cellular differentiation.

Pioneer Chromatin Engagement and Mesenchymal-to-Epithelial Transition

Single-cell transcriptomic and chromatin mapping reveal that somatic reprogramming unfolds over 14 to 21 days across three sequential phases:

1. Pioneer Nucleosome Binding (Days 1–3): As demonstrated by Abdenour Soufi, Kenneth S. Zaret, and colleagues (2012), OCT4, SOX2, and KLF4 act as pioneer transcription factors binding partial DNA motifs exposed on solvent-accessible nucleosome surfaces within silent chromatin and recruiting SWI/SNF (BAF) remodelers. c-MYC binds open promoters of cell-cycle and biosynthetic genes while stabilizing OSK enhancer occupancy, whereas megabase domains marked by H3K9me3 heterochromatin (maintained by SUV39H1/SETDB1 and CAF-1) initially exclude OSKM, accounting for the ~0.1–3% baseline reprogramming yield.
2. Mesenchymal-to-Epithelial Transition (MET, Days 3–9): Reprogramming fibroblasts silence mesenchymal regulators (SNAI1/2, ZEB1/2, TWIST1) while BMP signaling and KLF4 induce the miR-200 microRNA cluster, apical–basal polarity complexes, and E-cadherin (CDH1), compacting spindle fibroblasts into adherent epithelial microcolonies.
3. Endogenous Pluripotency Locking and Epigenetic Erasure (Days 10–21): Ten-eleven translocation dioxygenases (TET1 and TET2) oxidize 5-methylcytosine to 5-hydroxymethylcytosine across the promoters and enhancers of endogenous POU5F1, SOX2, NANOG, DPPA4, and DNMT3B, locking in a self-sustaining network matching embryonic stem cells once exogenous vectors silence. Concurrently, telomerase (TERT) elongates shortened somatic telomeres, bivalent H3K4me3/H3K27me3 domains re-form, and metabolism shifts toward glycolysis.

Epigenetic Age Rejuvenation vs. Late-Onset Disease Modeling

Full pluripotency induction via epigenetics remodeling resets DNA-methylation aging clocks (such as Steve Horvath's CpG clock) from elderly donor ages back to prenatal developmental age near zero, clearing senescent nuclear lamina defects and damaged mitochondria. Although valuable for regenerative grafting, this rejuvenation erases age-dependent cellular stress when modeling late-onset sporadic Alzheimer's or Parkinson's disease in iPSC-derived neurons, motivating direct fibroblast-to-neuron transdifferentiation (ASCL1/BRN2/MYT1L + microRNAs, which retains donor epigenetic age) or experimental aging via progerin expression.

Eliminating Polygenic Background Noise with Isogenic Pairs

Comparisons between patient iPSC lines and unrelated healthy controls suffer false positives because common polygenic variation between individuals often exceeds the effect size of a heterozygous mutation. Pairing human iPSCs with CRISPR–Cas9 gene editing, base editing, or prime editing creates isogenic control pairs—either repairing a patient mutation or knocking the variant into a reference line—isolating causal phenotypes across organoids, cerebral organoids, assembloids, and retinal organoids.

Autologous Grafts and HLA-Homozygous Clinical Haplobanks

In stem cell biology and regenerative medicine, autologous iPSCs avoid major histocompatibility complex (MHC) rejection without chronic immunosuppression, tested clinically in 2014 via autologous iPSC-derived retinal pigment epithelium transplantation (Masayo Takahashi) and in 2020 via autologous midbrain dopaminergic progenitors for Parkinson's disease. To reduce cost and manufacturing timelines, clinical initiatives such as Yamanaka's CiRA Foundation establish HLA-homozygous "super-donor" iPSC haplobanks—where 50 to 150 donors homozygous at HLA-A, HLA-B, and HLA-DRB1 match 70–90% of a regional population—alongside universal hypoimmunogenic iPSCs (B2M/CIITA knockout plus CD47 knock-in) supplying off-the-shelf dopaminergic neurons, cardiomyocyte sheets, β-islet cells, and iPSC-CAR-NK cancer immunotherapies.

Why did early iPSC protocols risk tumor formation, and how do clinical lines prevent it?

First-generation mouse iPSCs used integrating retroviruses carrying proto-oncogenic c-MYC; proviral reactivation or residual undifferentiated cells triggered teratomas or carcinomas in chimeras. Clinical GMP protocols eliminate this risk via non-integrating episomal, Sendai, or mRNA delivery, substituting non-transforming L-MYC (MYCL), whole-genome sequencing to exclude TP53 or BCOR variants, and selective purging of residual TRA-1-60⁺ undifferentiated cells before grafting.

Do iPSCs retain an epigenetic memory of their donor tissue?

At low passage numbers (passages 4–10), blood-derived vs. fibroblast-derived iPSCs transiently retain residual CpG hypomethylation near donor-lineage enhancers. Continued passaging past passage 15–20 resolves most tissue-of-origin marks, leaving donor genotype rather than starting cell type as the main driver of transcriptional variation across mature human iPSC lines.

How does chemical reprogramming induce human pluripotency without transcription-factor transgenes?

Jingyang Guan, Hongkui Deng, and colleagues (2022) showed that staged small-molecule inhibition of c-Jun N-terminal kinase (JNK), TGF-β, and GSK3 combined with retinoic-acid signaling and epigenetic modifiers guides human fibroblasts through an axolotl blastema-like plastic intermediate (LIN28A⁺/SALL4⁺/MSX1⁺) before activating endogenous OCT4–SOX2–NANOG pluripotency.

1. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663–676. https://doi.org/10.1016/j.cell.2006.07.024
2. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861–872. https://doi.org/10.1016/j.cell.2007.11.019
3. Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., ... & Thomson, J. A. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318(5858), 1917–1920. https://doi.org/10.1126/science.1151526
4. Soufi, A., Donahue, G., & Zaret, K. S. (2012). Facilitators and impediments of the pluripotency reprogramming factors' initial engagement with the genome. Cell, 151(5), 994–1004. https://doi.org/10.1016/j.cell.2012.09.045
5. Guan, J., Wang, G., Wang, J., Zhang, Z., Fu, Y., Cheng, L., ... & Deng, H. (2022). Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature, 605(7909), 325–331. https://doi.org/10.1038/s41586-022-04593-5